Changes in Purines Concentration in the Cerebrospinal Fluid of Pregnant Women Experiencing Pain During Active Labor

Imagem de Miniatura
Arquivos
art_SCHMIDT_Changes_in_Purines_Concentration_in_the_Cerebrospinal_Fluid_2015.PDF (615.65 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGER/PLENUM PUBLISHERS
Autores
SCHMIDT, Andre P.
BOEHMER, Ana E.
HANSEL, Gisele
SOARES, Felix A.
OSES, Jean P.
GIORDANI, Alex T.
MENDES, Florentino F.
FELIX, Elaine A.
Citação
NEUROCHEMICAL RESEARCH, v.40, n.11, p.2262-2269, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Labor pain has been reported as a severe pain and can be considered as a model of acute visceral pain. It is well known that extracellular purines have an important role in pain signaling in the central nervous system. This study analyzes the relationship between extracellular purines and pain perception during active labor. A prospective observational study was performed. Cerebrospinal fluid (CSF) levels of the purines and their metabolites were compared between women at term pregnancy with labor pain (n = 49) and without labor pain (Caesarian section; n = 47). Control groups (healthy men and women without chronic or acute pain-n = 40 and 32, respectively) were also investigated. The CSF levels of adenosine were significantly lower in the labor pain group (P = 0.026) and negatively correlated with pain intensity measured by a visual analogue scale (r = -0.48, P = 0.0005). Interestingly, CSF levels of uric acid were significantly higher in healthy men as compared to women. Additionally, pregnant women showed increased CSF levels of ADP, GDP, adenosine and guanosine and reduced CSF levels of AMP, GTP, and uric acid as compared to non-pregnant women (P < 0.05). These findings suggest that purines, in special the nucleoside adenosine, are associated with pregnancy and labor pain.
Palavras-chave
Purines, Adenosine, Acute pain, Cerebrospinal fluid, Labor pain, Visceral pain
URI
https://observatorio.fm.usp.br/handle/OPI/12592
Referências
  1. Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006
  2. Schmidt AP, 2010, NEUROSCI LETT, V474, P69, DOI 10.1016/j.neulet.2010.02.067
  3. PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039
  4. Sawynok J, 2003, PROG NEUROBIOL, V69, P313, DOI 10.1016/S0301-0082(03)00050-9
  5. Dickenson AH, 2000, CNS DRUGS, V13, P77, DOI 10.2165/00023210-200013020-00001
  6. Liao SL, 2001, NEUROSCI LETT, V299, P113, DOI 10.1016/S0304-3940(01)01499-9
  7. Sarchielli P, 2007, J PAIN, V8, P737, DOI 10.1016/j.jpain.2007.05.002
  8. Schmidt AP, 2010, BRIT J PHARMACOL, V159, P1247, DOI 10.1111/j.1476-5381.2009.00597.x
  9. Larson AA, 2000, PAIN, V87, P201, DOI 10.1016/S0304-3959(00)00284-0
  10. Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5
  11. Hsu MM, 2001, ANESTH ANALG, V93, P1293, DOI 10.1097/00000539-200111000-00053
  12. MELZACK R, 1993, PAIN, V53, P117, DOI 10.1016/0304-3959(93)90071-V
  13. CASTROGAGO M, 1995, EPILEPSIA, V36, P471, DOI 10.1111/j.1528-1157.1995.tb00488.x
  14. Watkins LR, 2003, NAT REV DRUG DISCOV, V2, P973, DOI 10.1038/nrd1251
  15. Lasley RD, 2011, BBA-BIOMEMBRANES, V1808, P1284, DOI 10.1016/j.bbamem.2010.09.019
  16. Schmidt AP, 2008, BRAIN RES, V1234, P50, DOI 10.1016/j.brainres.2008.07.091
  17. Schmidt AP, 2007, PEDIATR ANESTH, V17, P667, DOI 10.1111/j.1460-9592.2006.02185.x
  18. Alexander GM, 2007, BRAIN BEHAV IMMUN, V21, P668, DOI 10.1016/j.bbi.2006.10.009
  19. Sethuraman R, 2006, NEUROCHEM RES, V31, P1127, DOI 10.1007/s11064-006-9133-8
  20. Boison D, 2008, CURR OPIN PHARMACOL, V8, P2, DOI 10.1016/j.coph.2007.09.002
  21. Schmidt AP, 2010, J PAIN, V11, P131, DOI 10.1016/j.jpain.2009.06.010
  22. Oses JP, 2004, BRAIN RES BULL, V64, P237, DOI 10.1016/j.brainresbull.2004.07.006
  23. Portela LVC, 2002, BRAIN RES, V950, P74, DOI 10.1016/S0006-8993(02)02987-6
  24. Schmidt AP, 2007, PHARMACOL THERAPEUT, V116, P401, DOI 10.1016/j.pharmthera.2007.07.004
  25. SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5
  26. Sawynok J, 1999, EUR J PHARMACOL, V386, P253, DOI 10.1016/S0014-2999(99)00752-9
  27. Millan MJ, 1999, PROG NEUROBIOL, V57, P1, DOI 10.1016/S0301-0082(98)00048-3
  28. Domanski L, 2006, EUR J PHARM SCI, V27, P320, DOI 10.1016/j.ejps.2005.10.012
  29. Nakano H, 2001, PFLUG ARCH EUR J PHY, V442, P57, DOI 10.1007/s004240100521
  30. Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3
  31. GebickeHaerter PJ, 1996, NEUROCHEM INT, V29, P37, DOI 10.1016/0197-0186(95)00137-9
  32. Regner A, 1997, NEUROREPORT, V8, P3771, DOI 10.1097/00001756-199712010-00023
  33. Olofsson C, 1997, NEUROREPORT, V8, P995, DOI 10.1097/00001756-199703030-00035
  34. Blaug S, 2003, AM J PHYSIOL-CELL PH, V284, pC897, DOI 10.1152/ajpcell.00238.2002
  35. Gorodeski GI, 2002, AM J PHYSIOL-CELL PH, V282, pC75
  36. Inoue Kazuhide, 2005, Purinergic Signal, V1, P95, DOI 10.1007/s11302-005-6210-4
  37. Kawabe Masayuki, 2016, J Cardiol, V67, P170, DOI 10.1016/j.jjcc.2015.05.009
  38. Liu Xue Jun, 2005, Curr Opin Investig Drugs, V6, P65
  39. Mihaylova-Todorova ST, 2002, J PHARMACOL EXP THER, V302, P992, DOI 10.1124/jpet.102.033332
  40. Rodriguez-Nunez A, 2000, BRAIN DEV-JPN, V22, P427, DOI 10.1016/S0387-7604(00)00172-8
  41. Sawynok J, 1998, EUR J PHARMACOL, V317, P1
  42. Zimmermann H, 2001, DRUG DEVELOP RES, V52, P46

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/08